Raquel Bennet, Sunny Strasburg, Gita Vaid, Danielle M Herrera, Lauren Taus
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Psychedelic-assisted therapies for adolescents are discussed, including the use of ketamine for treatment-resistant depression and the need for further studies and careful consideration of risks. Traditional use of plant medicines
Corine de Boer, Rebecca Kronman, Glauber Assis
Ketamine and other psychedelics show promise for psychiatric disorders, but their psychoactive effects complicate masking in trials. A triple-masked trial on 40 patients with depression found surprising results.
Boris D. Heifets
Depression remains a major unmet medical need globally, with current medications often providing inadequate relief and leading to high costs. Psychedelic therapies, like psilocybin, show promise in revolutionizing mental health
Charles Raison
KAP program offers innovative treatment for adolescents with emotional issues, focusing on family involvement. Successes and challenges of this unique approach are discussed.
Phil Wolfson
Ayahuasca shows promise as a treatment for major depression, with a trial indicating significant reduction in symptoms and improvements in physiological systems linked to depression. Research on psychedelics for depression
Nicole Galvão-Coelho
Robin Carhart-Harris, Head of Centre for Psychedelic Research at Imperial College London, conducted pioneering clinical studies with psilocybin and other psychedelic drugs for over 40 years. He collaborates with Professor
Dr. Zeifman, Dr. Traynor, and Dr. Roberts explore the potential of psychedelic-assisted psychotherapy for Borderline Personality Disorder, discussing observational studies, promising research, and upcoming clinical trials in this symposium.
Daniel E Roberts, Jenna Traynor, Richard Zeifman
Results from the largest prospective survey of psilocybin use show that 30% of participants found the experience highly meaningful at 2-4 weeks, with positive effects on mental health persisting at
Sandeep Nayak, Nathan Sepeda, David Mathai
Psilocybin study shows personality changes and increased self-compassion in alcohol use disorder patients. Larger studies needed to confirm impact on AUD outcomes.
Broc A Pagni
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.